Roche provides update on leading late-stage pharmaceutical pipeline products

Swiss drug major Roche (ROG:SIX) this morning provided an update on its leading late-stage pipeline comprising 12 new molecular entities in key therapeutic areas at a London, UK, with focus on major progress that has been achieved in recent months with the firm’s late-stage pipeline assets in the areas of oncology and central nervous system (CNS), as well as on further development plans of these potential breakthrough medicines.

“Our goal is to continue delivering innovative medicines in therapeutic areas of high unmet need and to bring true medical value to patients. I am pleased that the glycine reuptake inhibitor and ocrelizumab - two molecules with the potential to treat severe diseases such as schizophrenia or multiple sclerosis are progressing to late-stage development,” said Hal Barron, head of global product development and chief medical officer of Roche. “We also see that the concept of Personalized Healthcare is becoming a reality for more and more of our development projects. MetMAb and the BRAF inhibitor are two encouraging examples for how personalized therapy could improve outcomes in lung cancer and melanoma, respectively,” he added

10 regulatory submissions expected by end-2013